Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial.

Victoria Federico PalyLaura Amanda Vallejo-AparicioAlan A Martin José Luis Izquierdo Juan Antonio Riesco MirandaJuan José Soler-CataluñaCatarina AbreuChandroday Biswas Afisi S Ismaila

Published in: International journal of chronic obstructive pulmonary disease (2022)

FF/UMEC/VI was predicted to be a cost-effective treatment option versus FF/VI or UMEC/VI in symptomatic COPD patients at risk of exacerbations in Spain, across all scenarios and sensitivity analyses.

Keyphrases

chronic obstructive pulmonary disease
lung function
cystic fibrosis
climate change
clinical trial
randomized controlled trial
combination therapy
phase ii
bone marrow
smoking cessation
double blind